SrasV1, 2020, Analysis, bibRecord, 000847

Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties.

Identifieur interne : 000847 ( 2020/Analysis ); précédent : 000846; suivant : 000848

Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties.

Auteurs : Cornelis Smit [Suisse] ; Mariska Y M. Peeters [Pays-Bas] ; John N. Van Den Anker [Suisse] ; Catherijne A J. Knibbe [Pays-Bas]

Source :

Clinical pharmacokinetics [ 1179-1926 ] ; 2020.

RBID : pubmed:32306288

Abstract

Since in vitro studies and a preliminary clinical report suggested the efficacy of chloroquine for COVID-19-associated pneumonia, there is increasing interest in this old antimalarial drug. In this article, we discuss the pharmacokinetics and safety of chloroquine that should be considered in light of use in SARS-CoV-2 infections. Chloroquine is well absorbed and distributes extensively resulting in a large volume of distribution with an apparent and terminal half-life of 1.6 days and 2 weeks, respectively. Chloroquine is metabolized by cytochrome P450 and renal clearance is responsible for one third of total clearance. The lack of reliable information on target concentrations or doses for COVID-19 implies that for both adults and children, doses that proved effective and safe in malaria should be considered, such as 'loading doses' in adults (30 mg/kg over 48 h) and children (70 mg/kg over 5 days), which reported good tolerability. Here, plasma concentrations were < 2.5 μmol/L, which is associated with (minor) toxicity. While the influence of renal dysfunction, critical illness, or obesity seems small, in critically ill patients, reduced absorption may be anticipated. Clinical experience has shown that chloroquine has a narrow safety margin, as three times the adult therapeutic dosage for malaria can be lethal when given as a single dose. Although infrequent, poisoning in children is extremely dangerous where one to two tablets can potentially be fatal. In conclusion, the pharmacokinetic and safety properties of chloroquine suggest that chloroquine can be used safely for an acute virus infection, under corrected QT monitoring, but also that the safety margin is small, particularly in children.

DOI: 10.1007/s40262-020-00891-1
PubMed: 32306288

Affiliations:

Links to Exploration step

pubmed:32306288

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties.</title>
<author><name sortKey="Smit, Cornelis" sort="Smit, Cornelis" uniqKey="Smit C" first="Cornelis" last="Smit">Cornelis Smit</name>
<affiliation wicri:level="1"><nlm:affiliation>Pediatric Pharmacology and Pharmacometrics Research Center, University of Basel Children's Hospital, Basel, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Pediatric Pharmacology and Pharmacometrics Research Center, University of Basel Children's Hospital, Basel</wicri:regionArea>
<wicri:noRegion>Basel</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Peeters, Mariska Y M" sort="Peeters, Mariska Y M" uniqKey="Peeters M" first="Mariska Y M" last="Peeters">Mariska Y M. Peeters</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Pharmacy, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Clinical Pharmacy, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein</wicri:regionArea>
<wicri:noRegion>Nieuwegein</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Van Den Anker, John N" sort="Van Den Anker, John N" uniqKey="Van Den Anker J" first="John N" last="Van Den Anker">John N. Van Den Anker</name>
<affiliation wicri:level="1"><nlm:affiliation>Pediatric Pharmacology and Pharmacometrics Research Center, University of Basel Children's Hospital, Basel, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Pediatric Pharmacology and Pharmacometrics Research Center, University of Basel Children's Hospital, Basel</wicri:regionArea>
<wicri:noRegion>Basel</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Knibbe, Catherijne A J" sort="Knibbe, Catherijne A J" uniqKey="Knibbe C" first="Catherijne A J" last="Knibbe">Catherijne A J. Knibbe</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands. c.knibbe@antoniusziekenhuis.nl.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden</wicri:regionArea>
<placeName><settlement type="city">Leyde</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32306288</idno>
<idno type="pmid">32306288</idno>
<idno type="doi">10.1007/s40262-020-00891-1</idno>
<idno type="wicri:Area/PubMed/Corpus">000030</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000030</idno>
<idno type="wicri:Area/PubMed/Curation">000030</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000030</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000669</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000669</idno>
<idno type="wicri:Area/Ncbi/Merge">003B71</idno>
<idno type="wicri:Area/Ncbi/Curation">003B71</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003B71</idno>
<idno type="wicri:Area/Main/Merge">000847</idno>
<idno type="wicri:Area/Main/Curation">000847</idno>
<idno type="wicri:Area/Main/Exploration">000847</idno>
<idno type="wicri:Area/2020/Extraction">000847</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties.</title>
<author><name sortKey="Smit, Cornelis" sort="Smit, Cornelis" uniqKey="Smit C" first="Cornelis" last="Smit">Cornelis Smit</name>
<affiliation wicri:level="1"><nlm:affiliation>Pediatric Pharmacology and Pharmacometrics Research Center, University of Basel Children's Hospital, Basel, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Pediatric Pharmacology and Pharmacometrics Research Center, University of Basel Children's Hospital, Basel</wicri:regionArea>
<wicri:noRegion>Basel</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Peeters, Mariska Y M" sort="Peeters, Mariska Y M" uniqKey="Peeters M" first="Mariska Y M" last="Peeters">Mariska Y M. Peeters</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Pharmacy, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Clinical Pharmacy, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein</wicri:regionArea>
<wicri:noRegion>Nieuwegein</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Van Den Anker, John N" sort="Van Den Anker, John N" uniqKey="Van Den Anker J" first="John N" last="Van Den Anker">John N. Van Den Anker</name>
<affiliation wicri:level="1"><nlm:affiliation>Pediatric Pharmacology and Pharmacometrics Research Center, University of Basel Children's Hospital, Basel, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Pediatric Pharmacology and Pharmacometrics Research Center, University of Basel Children's Hospital, Basel</wicri:regionArea>
<wicri:noRegion>Basel</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Knibbe, Catherijne A J" sort="Knibbe, Catherijne A J" uniqKey="Knibbe C" first="Catherijne A J" last="Knibbe">Catherijne A J. Knibbe</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands. c.knibbe@antoniusziekenhuis.nl.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden</wicri:regionArea>
<placeName><settlement type="city">Leyde</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Clinical pharmacokinetics</title>
<idno type="eISSN">1179-1926</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Since in vitro studies and a preliminary clinical report suggested the efficacy of chloroquine for COVID-19-associated pneumonia, there is increasing interest in this old antimalarial drug. In this article, we discuss the pharmacokinetics and safety of chloroquine that should be considered in light of use in SARS-CoV-2 infections. Chloroquine is well absorbed and distributes extensively resulting in a large volume of distribution with an apparent and terminal half-life of 1.6 days and 2 weeks, respectively. Chloroquine is metabolized by cytochrome P450 and renal clearance is responsible for one third of total clearance. The lack of reliable information on target concentrations or doses for COVID-19 implies that for both adults and children, doses that proved effective and safe in malaria should be considered, such as 'loading doses' in adults (30 mg/kg over 48 h) and children (70 mg/kg over 5 days), which reported good tolerability. Here, plasma concentrations were < 2.5 μmol/L, which is associated with (minor) toxicity. While the influence of renal dysfunction, critical illness, or obesity seems small, in critically ill patients, reduced absorption may be anticipated. Clinical experience has shown that chloroquine has a narrow safety margin, as three times the adult therapeutic dosage for malaria can be lethal when given as a single dose. Although infrequent, poisoning in children is extremely dangerous where one to two tablets can potentially be fatal. In conclusion, the pharmacokinetic and safety properties of chloroquine suggest that chloroquine can be used safely for an acute virus infection, under corrected QT monitoring, but also that the safety margin is small, particularly in children.</div>
</front>
</TEI>
<affiliations><list><country><li>Pays-Bas</li>
<li>Suisse</li>
</country>
<region><li>Hollande-Méridionale</li>
</region>
<settlement><li>Leyde</li>
</settlement>
</list>
<tree><country name="Suisse"><noRegion><name sortKey="Smit, Cornelis" sort="Smit, Cornelis" uniqKey="Smit C" first="Cornelis" last="Smit">Cornelis Smit</name>
</noRegion>
<name sortKey="Van Den Anker, John N" sort="Van Den Anker, John N" uniqKey="Van Den Anker J" first="John N" last="Van Den Anker">John N. Van Den Anker</name>
</country>
<country name="Pays-Bas"><noRegion><name sortKey="Peeters, Mariska Y M" sort="Peeters, Mariska Y M" uniqKey="Peeters M" first="Mariska Y M" last="Peeters">Mariska Y M. Peeters</name>
</noRegion>
<name sortKey="Knibbe, Catherijne A J" sort="Knibbe, Catherijne A J" uniqKey="Knibbe C" first="Catherijne A J" last="Knibbe">Catherijne A J. Knibbe</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/2020/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000847 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd -nk 000847 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    2020
   |étape=   Analysis
   |type=    RBID
   |clé=     pubmed:32306288
   |texte=   Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/RBID.i   -Sk "pubmed:32306288" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

Serveur d'exploration SRAS

Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties.

Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.